The SMN gene is implicated in spinal muscular atrophy (SMA), and its product has been shown to interact with Bcl-2 protein to enhance its anti-apoptotic activity. In this study, we determined the regions that were essential for the interaction of Bcl-2 and SMN by co-immunoprecipitation of deletion mutants. Bcl-2 lacking its amino-terminal 20 amino acid residues or its carboxyl-terminal membrane-anchoring domain showed no or greatly reduced binding with SMN, respectively. However, Bcl-2 lacking other regions could still bind to SMN. Because Bcl-2 lacking the membrane-anchoring domain could bind to SMN in a yeast two-hybrid system, the amino-terminal region of Bcl-2 seems to be the most important domain for binding with SMN. A fragment of SMN encoded by exon 6 could bind to Bcl-2, but SMN lacking this region could not. From these results, we concluded that Bcl-2 and SMN proteins bound with each other at the amino-terminal region near the BH4 domain of Bcl-2 and the region encoded by exon 6 of SMN, both regions known to be important for their function. Cell Death and Differentiation (2000) 7, 374 ± 383.
Introduction
Spinal muscular atrophy (SMA) is a common fatal autosomal recessive disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to progressive muscular atrophy. 1, 2 The survival motor neuron (SMN) gene has been shown to be the determining gene for SMA. 3 A region of the SMN gene at chromosome 5q13 is duplicated as an inverted repeat so that there exists an additional centromeric copy gene (termed c BCD541 or SMN c ) which has five silent base substitutions and possesses the identical protein-coding capacity as the telomeric SMN gene. The 5q13 region also contains other genes, NAIP, 4 BTF2p44 5,6 and H4F5, 7 which are deleted in some SMA patients and might also be involved in the pathogenesis of SMA.
More than 95% of SMA patients show deletion of both telomeric SMN alleles or deletion of one allele with mutation in the other allele. 3,8 ± 22 Consequently, only the centromeric copy of the SMN gene is functional in most SMA patients, and this produces both the full-length SMN transcript and a transcript lacking exon 5 or exon 7 by alternative splicing. 3 In contrast, the major product of the telomeric SMN gene is the full-length transcript. 3 A decrease of the SMN gene product 23 and/or changes in the ratio between full-length SMN and SMN lacking exons 5 or 7 3, 24 may underlie the pathogenesis of SMA. The latter concept is supported by the observation that several mutations in the telomeric SMN gene of patients with severe SMA lead to alternative splicing that produces transcripts lacking exon 7. 3 On the other hand, because gene conversion of telomeric SMN to SMN c , 25 ± 27 resulting in increase of SMN c gene copies, has been observed in some patients with mild SMA, 3, 14, 27, 28 a higher number of copies of the SMN c gene may reduce the severity of symptoms. However, other studies have not confirmed a correlation between SMN c gene copy number and disease severity. 24, 26, 29, 30 Four independent processes have been proposed as the physiological roles of the SMN gene product: (1) SMN interacts with hnRNP U, with itself, and with fibrillarin, a small nucleolar RNA binding protein, 31 or with SIP1 and snRNP Sm core proteins (including B/B' and D) during spliceosome synthesis, 32, 33 and thus influences the efficiency of splicing; 34 (2) SMN interacts directly with RNA; 35, 36 (3) SMN interacts with nuclear transcription activator E2 and thus influences E2-dependent transcriptional activation 37 and (4) SMN interacts with the antiapoptotic protein Bcl-2 to synergistically enhance its antiapoptotic activity.
that the BH3 domain is responsible for pro-apoptotic activity of this family. 39, 40 In most anti-apoptotic Bcl-2 family proteins, the BH4 domain at the amino terminal region is conserved in addition to the BH1, 2, and 3 domains, and it seems important for preventing apoptosis. 39, 40 A loop domain was also found by structural analysis of human Bcl-x L protein, 41 and it is thought to be involved in modulation of the activity of the anti-apoptotic family members, probably through phosphorylation. 42, 43 These proteins are partly regulated through interactions between selected pairs of pro-apoptotic and anti-apoptotic family members, 44 by binding of other proteins like Bag-1 45 and SMN, 38 or by chemical modifications including phosphorylation by Raf-1, 46 Akt, 47, 48 PKA, 49 or PKC. 50 Several functions of Bcl-2 have been proposed, such as prevention of apoptotic mitochondrial changes including cytochrome c release and membrane potential loss 51 ± 53 by closing the voltage-dependent anion channel (VDAC), 54 or binding and sequestering Apaf-1, a caspase-activating protein. 55 ± 59 We have previously shown that synergistic anti-apoptotic activity is not observed between Bcl-2 and SMN, Y272C a mutant found in some SMA patients, and that SMN/Bcl-2 synergism was cancelled by co-expression of SMN lacking the C-terminal region encoded by exon 7 (called SMNIa). 38 Thus, the dominant negative activity of SMNIa, whose proportion in all SMN products shows an increase in SMA patients, might play an important role in the pathogenesis of SMA. Because Bcl-2 expression in lower motor neurons is reduced after birth in both mice 60 and humans, 61 promotion of the anti-apoptotic activity of Bcl-2 by SMN might be required for lower motor neuron survival.
In the present study, we determined the essential regions for the binding of Bcl-2 with SMN as the first step towards understanding the mechanisms of their synergistic anti-apoptotic activity. We found that Bcl-2 and SMN bound to each other through the amino-terminal region near the BH4 domain of Bcl-2 and the region encoded by exon 6 of SMN.
Results

Essential region of Bcl-2 for binding to SMN
To understand the molecular mechanisms of the synergistic anti-apoptotic effect of human Bcl-2 (hBcl-2) and human SMN, we analyzed the interaction of these proteins. Haemagglutinin (HA)-tagged SMN protein (HA-SMN) was expressed together with hBcl-2 protein by transient cotransfection of COS-7 cells with two plasmids (pCAGGS-HA-SMN and pCAGGS-hbcl-2). After immunoprecipitation of cell lysates, the product was examined by Western blot analysis. When both HA-SMN and hBcl-2 were expressed, anti-HA antiserum, but not control antiserum, caused coimmunoprecipitation of hBcl-2 with HA-SMN ( Figure 1A) . Conversely, an anti-human Bcl-2 polyclonal antibody caused co-immunoprecipitation of HA-SMN with hBcl-2 (data not shown). On the other hand, co-immunoprecipitation of hBcl-2 was not detected when hBcl-2 was expressed without SMN ( Figure 1A ). These results indicated that SMN and hBcl-2 could interact with each other in mammalian cells, confirming our previous observations. 38 When chicken Bcl-2 or human Bcl-x L , homologues of human Bcl-2, were expressed with HA-SMN, neither of these proteins was co-immunoprecipitated with HA-SMN ( Figure 1B ,C). These findings suggested that human SMN binds specifically to human Bcl-2.
To determine the regions of human Bcl-2 that were necessary for specific binding to SMN, we constructed various human bcl-2 mutant genes. A series of deletion mutants were constructed as described in Materials and Figure 1 Co-immunoprecipitation of hBcl-2 and SMN. COS-7 cells were transfected with the indicated plasmids, and cell lysates were subjected to immunoprecipitation (IP) using anti-HA rabbit antiserum (a-HA) and normal rabbit serum (NRS) as the control, as described in Materials and Methods. After gel electrophoresis, hBcl-2 (A), cBcl-2 (B) and hBcl-x L (C) proteins in immunoprecipitates were detected by Western blotting using an anti-hBcl-2 monoclonal antibody (A), an anti-cBcl-2 mouse monoclonal antibody (B), and an anti-hBcl-x L mouse monoclonal antibody (C), respectively. Part of each precleared lysate obtained before immunoprecipitation was also loaded (lysate) Methods, and are shown in Figure 2 . D1, D2, D5, D6, D8, D9, D10 and D11 each lacked 20 amino acid residues, and only D7 lacked 24 amino acid residues ( Figure 2 ). Two mutants, Dloop and D12, were also constructed without the loop domain and the membrane-anchoring domain of hBcl-2, respectively ( Figure 2 ). Each mutant gene was subcloned into the pUC-CAGGS expression plasmid.
Using these deletion mutants of bcl-2, we examined the regions of hBcl-2 that were essential for binding to SMN by immunoprecipitation. We first examined the interaction of SMN with hBcl-2 lacking the regions mostly covering the BH1, 2, and 3 domains and loop domain. When hBcl-2 Dloop, D5, D8, and D10 mutants were expressed together with SMN in COS-7 cells, anti-HA antiserum co-immunoprecipitated these hBcl-2 proteins with HA-SMN to a similar extent as occurred with the full-length hBcl-2 protein ( Figure  3A ), indicating that the BH1, 2, 3 domains and the loop domain were not required for binding of hBcl-2 to SMN. Similarly, hBcl-2 D2, D6, D7, D9 and D11 proteins were coimmunoprecipitated with HA-SMN by anti-HA antiserum ( Figure 3B ), indicating that the regions removed in these proteins were also non-essential for the interaction of hBcl-2 with SMN.
In contrast, deletion of the amino terminal 20 amino acid residues near the BH4 domain of hBcl-2 (hBcl-2 D1) completely abolished the interaction of hBcl-2 with HA-SMN ( Figure 3C ). Consistently, an anti-human Bcl-2 polyclonal antibody did not co-immunoprecipitate HA-SMN with hBcl-2 D1 protein (data not shown). Deletion of the membraneanchoring domain of hBcl-2 (hBcl-2 D12) greatly reduced the interaction with SMN ( Figure 3D ). From these results, we concluded that two domains near the BH4 and membrane-anchoring domains were important for the binding of hBcl-2 with SMN.
Essential region of SMN for binding to hBcl-2
To determine the region of SMN that was essential for interaction with hBcl-2, we constructed the following exonbased deletion mutants of SMN: SMNexon1234, SMNexon567, SMNexon56, SMNexon5, and SMNexon6 ( Figure 4) . All of the mutants were HA-tagged and subcloned into the pUC-CAGGS expression vector.
We then analyzed the interaction of the products of these SMN deletion mutants with hBcl-2 by immunoprecipitation. As shown in Figure 5A , hBcl-2 was not coimmunoprecipitated with SMNexon1234. On the other hand, hBcl-2 was detected in the immunoprecipitates by anti-HA antiserum when expressed together with SMNexon567 and exon56 ( Figure 5B), suggesting that the region coded by exons 5 and 6 of the SMN gene was responsible for binding to hBcl-2. To determine whether exons 5 or 6 alone was sufficient for binding, we next examined the interaction of SMNexon5 and SMNexon6 with hBcl-2. As shown in Figure 5C , hBcl-2 was coimmunoprecipitated with SMNexon6 by anti-HA serum, but 
Discussion
The SMN gene is implicated in the pathogenesis of SMA. Several actions of the SMN gene product have been proposed to contribute to SMA, such as involvement in splicing 34 and enhancement of the anti-apoptotic activity of hBcl-2 protein. 38 In the present study, we determined the essential regions for the interaction of hBcl-2 and SMN using deletion mutants. We found that hBcl-2 lacking the aminoterminal 20 amino acid residues did not show any detectable binding to SMN, while hBcl-2 lacking the membraneanchoring domain (hBcl-2 D12) showed greatly reduced binding. Because hBcl-2 D12 bound to SMN in a yeast twohybrid system, 38 these results strongly suggest that hBcl-2 binds to SMN through the amino-terminal region near BH4. The membrane-anchoring domain of hBcl-2 is required for its localization to the membrane, and hBcl-2 lacking the membrane-anchoring domain moves to the cytoplasm. 62 Therefore, the greatly reduced binding between SMN and hBcl-2 D12 might have been due to its change in subcellular localization, since there is little SMN in the cytoplasm. 38 We also found that the region encoded by exon 6 of SMN bound to hBcl-2, and SMN lacking this region did not, suggesting that the region encoded by exon 6 was responsible for binding to hBcl-2. From these results, we concluded that hBcl-2 and SMN bind to each other through the amino-terminal region of hBcl-2 near BH4 and the region of SMN encoded by exon 6.
A comparison of the amino acid sequences of the amino terminal regions of hBcl-2, cBcl-2 and hBcl-x L is shown in Figure 6 . BH4 spans the regions deleted in hBcl-2 D1 and D2. Because hBcl-2 D2 binds with SMN, the C-terminal half of BH4 should not be involved in this interaction. Although the N-terminal half of BH4, corresponding to the C-terminal half of the region deleted in hBcl-2 D1, contains some substitutions of amino acid residues between hBcl-2 and hBcl-x L , the substituted residues have a similar hydrophobicity, so that the region is well conserved among these proteins. However, the N-terminal half of the region deleted in hBcl-2 D1 shows marked differences between hBcl-2 and hBcl-x L , especially hBcl-2 having extra six amino acid residues. Because cBcl-2 did not bind to SMN, the difference of the amino acid residues in these regions of hBcl-2 and cBcl-2 might be responsible for the SMNbinding ability. These observations suggest that SMN might recognize the N-terminal half of the region deleted in hBcl-2 D1. Figure 7 shows a comparison of the 3D-structures of hBcl-x L and hBcl-2. Based on the published structures of human Bcl-x L 41 and rat Bcl-x L , 63 the structure of hBcl-2 was predicted by computer modeling. Because no information was available on the N-terminal six amino acid residues and the loop regions of hBcl-2, the positions of the residues in these regions are not displayed. The overall structures of both proteins are similar, but some critical differences can be seen around BH4. The N-terminal a-helix (a1) of hBcl-2 is shorter than that of hBcl-x L , and the distribution of acidic and basic amino acid residues in a1 differs between hBcl-2 and hBcl-x L . The a1 region almost covers BH4, which is conserved in many anti-apoptotic Bcl-2 family proteins and is important for the prevention of apoptosis. 64 ± 68 Several biochemical functions of BH4 region have been proposed. BH4 region of hBcl-x L was reported to be required for interaction with Ced-4 (a C. elegans homolog of Apaf-1) to form apoptosome. 68 We have recently shown that the BH4 oligopeptides of hBcl-x L and hBcl-2 could shut off the voltage-dependent anion channel (VDAC) in the same way as the full-length proteins in a reconstituted VDAC-liposome system and these peptides can also prevent apoptotic changes in isolated mitochondria and apoptotic cell death. 69 Binding of SMN to the N-terminal half of the region deleted in hBcl-2 D1 might induce conformational changes in BH4. Because a1 is laid on the body of hBcl-2, conformational changes of BH4 might expose this region, and the exposure of BH4 by SMN might increase the antiapoptotic activity of hBcl-2 possibly by increasing the affinity to VDAC and/or Apaf-1/Ced-4. Alternatively, the possible conformational changes induced by binding of SMN might stabilize the a-helix (a1) of hBcl-2, and may mediate the full anti-apoptotic activity of hBcl-2. Although we failed to detect any interaction between SMN and hBcl-2 peptides containing the region deleted in hBcl-2 D1 and BH4 (unpublished observations), this may have been caused by the conformational differences of a1 in solution relative to that on the protein. To elucidate the reason for the enhanced anti-apoptotic activity of Bcl-2 bound to SMN, structural analysis of the hBcl-2/SMN complex is probably necessary.
The region encoded by exon 6 is the most highly conserved region of SMN protein from yeast and C. elegans through mammals. 18, 36, 70 This region was reported to be responsible for binding to Sm core proteins, 32 selfassociation, 71 and binding to transcription activator E2. 37 Analysis of missense mutations of the SMN gene in SMA patients with heterozygous telomeric SMN gene deletion has shown that these mutations cluster in exon 6. Essential regions for Bcl-2/SMN interaction K Sato et al nonsense mutations, so that SMN protein containing exon 6 was not produced by these mutants. These observations strongly suggest that the region encoded by exon 6 is the most important domain of SMN protein to exert its function. Actually, SMN protein with amino acid substitution Y 272 C in the exon 6 region, which has been found in some SMA patients, does not show any synergism with Bcl-2. 38 We speculate that the lack of synergistic effect with Bcl-2 of the SMNIa mutant lacking exon 7 is due to the conformational change of SMN protein by loss of the region. Alternatively, the region encoded by exon 6 may serve as the binding site for Bcl-2, and the functional site may reside in the region encoded by exon 7. Taken together with the fact that the exon 6 region of the SMN gene binds to hBcl-2 protein, the binding of SMN to Bcl-2 at this region seems likely to ensure motor neuron survival. Loss of the interaction and the synergistic anti-apoptotic activity seems to underlie the pathogenesis of SMA. 
Materials and Methods
Plasmids pCAGGS-hbcl-2 and pCAGGS-HA-SMN were described previously. 38 hBcl-2 deletion mutants were constructed by using HindIII linker to join upstream and downstream fragments obtained by polymerase chain reaction (PCR). The hBcl-2D1, D2, Dloop, D5, D6, D7, D8, D9, D10, D11, and D12 genes lacked the regions coding for a.a. 2 ± 21, 22 ± 41, 31 ± 92, 81 ± 100, 102 ± 121, 122 ± 145, 142 ± 161, 162 ± 181, 182 ± 201, 202 ± 221, 222 ± 239 of hBcl-2, respectively. SMN deletion mutants were also constructed by PCR with the nine codons of the Figure 6 Alignment of the amino acid sequences of the N-terminal regions of hBcl-2, cBcl-2, and hBcl-x L . The amino acid sequences of the N-terminal regions of hBcl-2, cBcl-2, and hBcl-x L are shown. Regions corresponding to BH4 and removed in hBcl-2 D1 and D2 are indicated. Residues conserved in more than two proteins are highlighted Figure 7 Comparison of the 3D-structure of hBcl-x L and hBcl-2. Ribbon models of hBcl-x L (A and C) and hBcl-2 (B and D) are shown. The X-ray structure of hBclx L (entry 1MAZ in the Brookhaven database) was depicted using WebLab ViewerLite, and the structure of hBcl-2 was generated as described in Materials and Methods. The 1st to 27th and 81st to 196th residues of hBcl-x L are shown, as are the 6th to 32nd and 87th to 203rd residues of hBcl-2. The first a-helix (a1) is colored yellow and the positions of a5 and a6 are shown in A and B. In C and D, acidic and basic residues are shown in blue and red, respectively 
Antibodies
The antibodies used were as follows: anti-hBcl-2 hamster monoclonal antibody (Pharmingen; clone 6C8), anti-hBcl-2 rabbit polyclonal antibody (a-hBcl-2), 77 anti-hBcl-x L mouse monoclonal antibody (Transduction; clone 44), anti-cBcl-2 mouse monoclonal antibody (prepared for this study), anti-HA tag rabbit antiserum (a-HA: Medical and Biological Laboratories, Japan), and anti-HA tag mouse monoclonal antibody (Boehringer Mannheim; clone 12CA5). Normal rabbit serum (NRS: Medical and Biological Laboratories, Japan), normal mouse IgG2b (NMI: Bethyl), and normal rabbit IgG (Medical and Biological Laboratories, Japan) were used as control antibodies for anti-HA tag rabbit antiserum, 12CA5, and the other rabbit polyclonal antibodies, respectively.
Transfection and immunoprecipitation
COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), L-glutamine (2 mM) and 0.45% glucose at 378C under humidified 10% CO 2 . The indicated combinations of pCAGGS-hbcl-2, pCAGGS-HA-SMN, and their mutant constructs were transfected into COS-7 cells (at 50% confluence in 10-cm dishes), using LipofectAmine (Gibco) and 5 mg of each plasmid. In some cases, pCAGGS-cbcl-2 or pCAGGS-hbcl-x L was transfected together with pCAGGS-HA-SMN. Cells were incubated for 36 ± 42 h in DMEM supplemented with 10% FBS and were harvested for immunoprecipitation. The following procedures were carried out at 48C. After washing with PBS, cells were lysed by sonication in lysis buffer (10 mM HEPES, pH 7.5, 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EGTA, 0.2% NP-40, 0.1 mM p-APMSF, 10 mg/ml aprotinin, 1 mg/ml pepstatin, and 1 mg/ml leupeptin). Cell debris were removed by centrifugation at 15 0006g for 15 min. Lysates were precleared with control antibodies and 5% (v/v) protein G-sepharose (Pharmacia) for 60 min, and were subsequently incubated with specific antibodies for 90 min. Immunoprecipitates were captured with 5% (v/v) protein G-sepharose for 60 min, and were washed five times with lysis buffer. Immunoprecipitates from 10 5 cells were solubilized in SDS ± PAGE sample buffer, subjected to SDS ± PAGE on 12.5% gels and transferred to an Immobilon polyvinylidene difluoride membrane (Millipore). Part of each precleared lysate obtained before immunoprecipitation was also loaded to show equivalence of the amount of proteins in lysates. The filters were incubated with specific antibodies and the bound antibody was visualized using horseradish peroxidase-conjugated specific secondary antibodies combined with a chemiluminescence enhancer (ECL, Amersham).
Computer modeling of Bcl-2
The structure of human Bcl-2 was modeled by ProModII 78 on a SWISS-MODEL Automated Protein Modeling Server. Modeling was based upon the coordinates of the X-ray structures of human Bcl-x L , 41 and rat Bcl-x L , 63 as well as NMR minimized average structures of human Bcl-x L 41 and human Bcl-x L /Bak peptide complex, 79 obtained from the Brookhaven database (accession Nos. 1MAZ, 1AF3, 1LXL, and 1BXL, respectively). Energy minimization was carried out using GROMOS96 80 with IFP43B1 as a parameter set, involving 200 cycles of steepest descent to satisfy 25/C-Factors and 300 cycles of conjugate gradient to satisfy 2500/C-Factors.
